A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 With and Without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EO 2002 (Primary)
Indications Corneal disorders
Focus Adverse reactions; Proof of concept
Acronyms EMME-01
Sponsors Emmecell

Most Recent Events

18 Nov 2024 Results presented in the Emmecell media release.
08 Oct 2024 According to Emmecell media release, Emmecell Completes last patient last visit in its phase 1 extension study EMME-001 and additional detailed topline results are expected to be reported in the next month for all subjects treated across three doses of EO2002.
30 Apr 2024 According to Emmecell media release, topline results from this trial are expected in second half of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight